The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Susan F. Slovin
Consulting or Advisory Role - Bayer; Clovis Oncology; Pfizer
Speakers' Bureau - OncLive; PER; Prime Oncology; Society for Immunotherapy of Cancer
Research Funding - AstraZeneca
 
Tanya B. Dorff
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen Oncology; Noxopharm; Seagen
Research Funding - Pfizer (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Navire (Inst); Predicine (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Silicon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Xiao X. Wei
Honoraria - OncLive
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Xin Gao
Consulting or Advisory Role - Bayer; Dendreon; Exelixis; Flare Therapeutics; Guardant Health
Research Funding - Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Merck (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
David Yoonsuk Oh
Consulting or Advisory Role - Maze Therapeutics
Research Funding - Merck (Inst); PACT Pharma (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - Roche/Genentech
 
Andreas Georg Wibmer
No Relationships to Disclose
 
Matthew A. Spear
Employment - Poseida Therapeutics
Leadership - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Joanne McCaigue
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Devon J. Shedlock
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Manjima Dhar
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
Consulting or Advisory Role - Poseida Therapeutics
 
Julia Coronella
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Christopher E. Martin
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Majid Ghodussi
Employment - Poseida Therapeutics
Leadership - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Ann Murphy
Employment - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
 
Eric M. Ostertag
Employment - Poseida Therapeutics
Leadership - Poseida Therapeutics
Stock and Other Ownership Interests - Poseida Therapeutics
Patents, Royalties, Other Intellectual Property - poseida therapeutics
Travel, Accommodations, Expenses - Poseida Therapeutics